Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068386 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4ENPSR1HSD17B10TSHR | |
| SCHEMBL7066749 | 0.87 | MEN1 (0.45) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL7066752 | 0.87 | MEN1 (0.45) | ALDH1A1KDM4EHSD17B10KMT2ASMN1; SMN2 | |
| SCHEMBL7087655 | 0.85 | GAA (0.51) | ALDH1A1KDM4ENPSR1TSHRKMT2A | |
| SCHEMBL7087657 | 0.85 | GAA (0.51) | ALDH1A1KDM4ENPSR1TSHRKMT2A | |
| SCHEMBL7065449 | 0.83 | ITGB3 (0.40) | ALDH1A1TSHRCYP2C9SMN1; SMN2 | |
| SCHEMBL7065445 | 0.83 | ITGB3 (0.40) | ALDH1A1TSHRCYP2C9SMN1; SMN2 | |
| SCHEMBL7071239 | 0.82 | SMN1; SMN2 (0.56) | ALDH1A1KDM4EKMT2ACYP3A4CYP2C9 | |
| SCHEMBL7071236 | 0.82 | SMN1; SMN2 (0.56) | ALDH1A1KDM4EKMT2ACYP3A4CYP2C9 | |
| SCHEMBL7066741 | 0.82 | TSHR (0.46) | ALDH1A1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073701-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | ALDH1A1 3091/4885KDM4E 3430/4885NPSR1 1539/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | ALDH1A1 3091/4885KDM4E 3430/4885NPSR1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.